Track Centessa Pharmaceuticals Limited — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Centessa Pharmaceuticals Limited CNTA · Stock Open Centessa Pharmaceuticals Limited in new tab

40.50 USD
Add to portfolio
EPS
-1.78
P/B
12.86
ROE
-57.38
Beta
1.12
Target Price
40.25 USD
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateAug. 11, 2026
EPS-1.78
Book Value3.15
Price to Book12.86
Debt/Equity24.33
% Insiders0.670%
Estimates
Forward P/E-22.75
Forward EPS-1.78
Target Mean Price40.25

DCF Valuation

Tweak assumptions to recompute fair value for Centessa Pharmaceuticals Limited (CNTA)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Centessa Pharmaceuticals Limited Logo Centessa Pharmaceuticals Limited Analysis (CNTA)

United Kingdom Health Care Official Website Stock

Is Centessa Pharmaceuticals Limited a good investment? Centessa Pharmaceuticals Limited (CNTA) is currently trading at 40.50 USD. Market analysts have a consensus price target of 40.25 USD. This suggests the asset is currently trading above analyst expectations.

Earnings Schedule: Centessa Pharmaceuticals Limited is expected to release its next earnings report on Aug. 11, 2026. The market consensus estimate for Forward EPS is -1.78.

Investor FAQ

Does Centessa Pharmaceuticals Limited pay a dividend?

No, it does not currently pay a dividend.

What asset class is Centessa Pharmaceuticals Limited?

Centessa Pharmaceuticals Limited is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Aug. 11, 2026. The company currently has a trailing EPS of -1.78.

Company Profile

Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia. It also engages in the development of ORX142 which is in Phase I clinical trial for the treatment of neurological and neurodegenerative disorders; ORX489 which is in Phase I clinical trial for the treatment of neuropsychiatric disorders; and LockBody, an early-stage immuno-oncology program technology platform. The company was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Exchange Ticker
NMS (United States) CNTA
Trades
Dividend History paid per year (USD)
Historical Dividends
Year Total Dividends
▸2026
38.00 USD
June 24, 2026 38.0000
Upcoming Dividends
Name Payment Date Status Amount
Centessa Pharmaceuticals Limited Jun 24, 2026 38.0 USD
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion